Main cancers (summary list)

Five-year relative survival by stage at diagnosis (2003-2007 diagnosis period)

			Five-year relative survival (with 95% confidence interval) by stage at diagnosis (2003-2007)
Cancer type	Sex	Age at diagnosis	Total	Stage I	Stage II	Stage III	Stage IV	Unknown


head & neck	both	all 15-99	50.3%	88.0%	66.6%	50.6%	31.6%	56.2%
(ICD10 C01-C06,C09-C13)		(unstandardized)	(46.1-54.4%)	(78.5-94.8%)	(53.6-77.7%)	(40.6-59.9%)	(25.9-37.4%)	(43.4-68.0%)


oesophagus	both	all 15-99	15.8%	45.3%	34.6%	14.4%	5.6%	11.6%
(ICD10 C15)		(unstandardized)	(13.3-18.6%)	(26.3-64.2%)	(26.2-43.2%)	(8.1-22.7%)	(3.1-8.2%)	(8.2-15.8%)


stomach	both	all 15-99	23.9%	74.1%	42.7%	18.6%	4.8%	17.5%
(ICD10 C16)		(unstandardized)	(21.4-26.4%)	(63.0-83.8%)	(33.2-52.1%)	(13.5-24.3%)	(3.0-7.3%)	(12.8-23.0%)


colorectal	both	all 15-99	57.6%	92.1%	78.2%	61.5%	10.6%	47.4%
(ICD10 C18-C21)		(unstandardized)	(56.0-59.1%)	(88.3-95.6%)	(75.1-81.0%)	(58.4-64.5%)	(8.67-12.6%)	(41.4-53.4%)

colorectal	both	all 15-99	57.0%	90.8%	77.6%	60.7%	10.2%	51.9%
(ICD10 C18-C21)		(age-standardized)#	(53.7-60.2%)


colon	both	all 15-99	57.7%	93.3%	80.8%	61.3%	10.1%	40.8%
(ICD10 C18)		(unstandardized)	(55.7-59.6%)	(88.1-97.7%)	(77.1-84.2%)	(57.2-65.3%)	(7.9-12.6%)	(33.0-48.9%)


rectum/anus	both	all 15-99	57.4%	88.5%	72.2%	61.8%	11.5%	52.3%
(ICD10 C19-C21)		(unstandardized)	(54.8-59.8%)	(82.6-93.5%)	(66.7-77.2%)	(56.9-66.3%)	(8.1-15.4%)	(43.6-60.8%)


			Five-year relative survival (with 95% confidence interval) by stage at diagnosis (2003-2007)
Cancer type	Sex	Age at diagnosis	Total	Stage I	Stage II	Stage III	Stage IV	Unknown


pancreas	both	all 15-99	6.2%	9.3%	6.2%	7.9%	2.9%	9.9%
(ICD10 C25)		(unstandardized)	(4.6-8.0%)	(4.4-16.7%)	(0.8-20.7%)	(2.6-17.4%)	(1.7-4.7%)	(6.3-14.4%)


liver	both	all 15-99	12.9%	40.1%	22.6%	16.7%	7.7%	9.8%
(ICD10 C22)		(unstandardized)	(9.4-17.0%)	(15.9-65.0%)	(7.6-43.6%)	(8.8-26.9%)	(4.2-12.7%)	(4.2-18.5%)


larynx	both	all 15-99	57.9%	80.8%	62.9%	45.6%	24.5%	67.1%
(ICD10 C32)		(unstandardized)	(51.8-63.7%)	(67.8-90.6%)	(46.4-77.1%)	(32.8-58.0%)	(15.5-34.8%)	(49.7-81.8%)


lung & trachea	both	all 15-99	11.7%	34.6%	26.2%	7.0%	3.2%	10.5%
(ICD10 C33-C34)		(unstandardized)	(10.7-12.7%)	(30.2-39.0%)	(20.9-31.8%)	(5.5-8.7%)	(2.4-4.1%)	(8.0-13.4%)

lung & trachea	both	all 15-99	12.7%	-	25.3%	8.0%	3.2%	-
(ICD10 C33-C34)		(age-standardized)#


melanoma of skin	both	all 15-99	86.6%	98.2%	82.7%	63.7%	27.1%	85.4%
(ICD10 C43)		(unstandardized)	(84.1-88.8%)	(95.7-100%)	(76.3-88.3%)	(55.7-71%)	(16.9-38.6%)	(75.4-93.3%)

melanoma of skin	both	all 15-99	86.0%	96.8%	82.5%	60.6%	32.0%	84.5%
(ICD10 C43)		(age-standardized)#	(80.5-90.5%)


soft tissue	both	all 15-99	63.3%	90.2%	68.8%	-	24.5%	65.7%
(ICD10 C47 & C49)		(unstandardized)	(56.1-70.0%)	(59.3-99.9%)	(37.2-88.9%)		(11.8-40.0%)	(55.0-75.2%)


			Five-year relative survival (with 95% confidence interval) by stage at diagnosis (2003-2007)
Cancer type	Sex	Age at diagnosis	Total	Stage I	Stage II	Stage III	Stage IV	Unknown


breast	female	all 15-99	85.0%	98.9%	90.2%	67.3%	27.7%	71.2%
(ICD10 C50)		(unstandardized)	(83.8-86.1%)	(97.6-100.0%)	(88.5-91.6%)	(63.2-71.1%)	(23.1-32.5%)	(62.9-78.8%)

breast	female	all 15-99	81.8%	97.1%	88.7%	66.1%	27.6%	69.8%
(ICD10 C50)		(age-standardized)#	(78.6-84.7%)


cervix uteri	female	all 15-99	66.2%	90.9%	57.1%	44.9%	15.7%	61.5%
(ICD10 C53)		(unstandardized)	(62.2-69.8%)	(85.9-94.3%)	(46.1-66.7%)	(35.2-54.2%)	(7.9-25.9%)	(49.0-72.1%)


corpus uteri	female	all 15-99	77.3%	91.3%	79.1%	58.3%	24.9%	61.7%
(ICD10 C54)		(unstandardized)	(73.6-80.6%)	(87.1-94.6%)	(66.5-88.4%)	(42.8-71.8%)	(14.4-37.1%)	(45.3-76.8%)


ovary & uterine adnexa	female	all 15-99	38.9%	86.4%	50.5%	22.5%	14.8%	21.8%
(ICD10 C56 & C57.0-57.7)~		(unstandardized)	(35.6-42.1%)	(80.8-90.8%)	(36.8-63.4%)	(17.2-28.3%)	(10.7-19.5%)	(13.5-31.6%)


prostate	male	all 15-99	92.8%	98.8%	99.9%	96.8%	35.7%	90.2%
(ICD10 C61)		(unstandardized)	(91.5-94.0%)	(91.8-100%)	(98.4-100%)	(93.0-100%)	(31.1-40.4%)	(86.8-93.3%)

prostate	male	all 15-99	89.9%	97.3%	97.7%	92.0%	37.5%	89.2%
(ICD10 C61)		(age-standardized)#	(86.7-92.8%)


testis	male	all 15-99	97.0%	98.5%	98.5%	83.7%	not	94.7%
(ICD10 C62)		(unstandardized)	(95.0-98.3%)	(95.5-99.7%)	(94.9-99.7%)	(73.3-90.3%)	applicable	(67.5-99.3%)


			Five-year relative survival (with 95% confidence interval) by stage at diagnosis (2003-2007)
Cancer type	Sex	Age at diagnosis	Total	Stage I	Stage II	Stage III	Stage IV	Unknown


kidney & related	both	all 15-99	57.5%	87.5%	85.3%	60.7%	12.7%	31.6%
(ICD10 C64-66 & C68)		(unstandardized)	(54.0-60.8%)	(81.7-92.3%)	(75.7-92.8%)	(51.9-68.8%)	(8.8-17.3%)	(19.3-45.7%)


bladder	both	all 15-99	69.4%	85.9%	49.0%	44.3%	16.7%	73.2%
(ICD10 C67)		(unstandardized)	(65.9-72.7%)	(78.7-92.3%)	(39.9-57.9%)	(34.1-54.4%)	(10.1-24.8%)	(66.8-79.3%)


thyroid	both	all 15-99	84.7%	98.8%	86.7%	66.0%	21.7%	69.5%
(ICD10 C73)		(unstandardized)	(78.7-89.4%)	(96.0-99.9%)	(67.8-96.9%)	(44.4-82.1%)	(5.6-46.1%)	(54.3-81.4%)


Hodgkin lymphoma	both	all 15-99	87.5%	91.9%	93.8%	64.7%	80.1%	80.5%
(ICD10 C81)		(unstandardized)	(83.2-91.0%)	(82.1-97.5%)	(88.8-96.9%)	(50.1-76.6%)	(65.7-89.6%)	(54.1-93.2%)


non-Hodgkin lymphoma	both	all 15-99	67.7%	77.0%	71.0%	63.0%	57.9%	66.2%
(ICD10 C82-C85 & C96)		(unstandardized)	(64.9-70.3%)	(72.0-81.7%)	(64.2-77.1%)	(56.0-69.5%)	(52.2-63.3%)	(58.7-73.1%)

Footnotes:

AJCC stage (5th edition) is used here.

Patients with unspecified nodal status (N category) or distant metastatic status (M category) have been assumed to be N0 and M0, respectively.

This may result in some underestimation of survival for Stage I-III cases (particularly in older age-groups).

Cases with unspecified T category are left unstaged unless N & M categories are sufficient to allow staging.

# Age-standardized figures use the standard patient population proposed for the relevant cancer by:

Corazziari I., Quinn M. & Capocaccia R. 2004. Standard cancer patient population for age standardising survival ratios. Eur J Cancer 40: 2307-2316.

Exclusions (as in EUROCARE):

Patients aged <15 or >99 at diagnosis; death-certificate-only (DCO) and autopsy-only cases; second or subsequent malignancies in the same patient

(or the less serious of two or more synchronously-diagnosed malignancies); in situ carcinomas and tumours of uncertain behaviour.

- = insufficient data